GETTING MY SEVITERONEL TO WORK

-mutated tumors. Nevertheless, merely a portion of those patients responds to immune checkpoint or PARP inhibitors and in many cases those that do reply often produce resistance and relapse.Mechanistically, we report differential binding of AR to target genes while in the existence of enzalutamide and seviteronel, suggesting different mechanisms of